Site Editor

William J. Gradishar, MD, FACP, FASCO


Novel Triplet Under Study in Advanced Immunomodulatory Triple-Negative Breast Cancer

By: Julia Fiederlein
Posted: Wednesday, May 25, 2022

The tyrosine kinase inhibitor famitinib plus the monoclonal antibody camrelizumab and nab-paclitaxel seemed to be safe and active in patients with previously untreated, advanced, immunomodulatory triple-negative breast cancer, according to Zhi-Ming Shao, MD, of the Key Laboratory of Breast Cancer in Shanghai, and colleagues. The results of the phase II FUTURE-C-Plus trial, which were published in Clinical Cancer Research, support this novel triplet regimen as a potential first-line treatment option. To validate these findings, the randomized, controlled FUTURE-SUPER trial is under way.

“This is the first study to use this approach in this subtype of breast cancer,” the investigators commented. “[It demonstrated] the best objective response rate reached in the first-line setting to treat patients with metastatic triple-negative breast cancer.”

A total of 48 patients with previously untreated, advanced, immunomodulatory triple-negative breast cancer were administered oral famitinib (20 mg on days 1–28), intravenous camrelizumab (200 mg on days 1 and 15), and intravenous nab-paclitaxel (100 mg/m2 on days 1, 8, and 15) in 4-week cycles. Follow-up data were provided for a median of 17 months.

The confirmed objective response rate was 81.3%; this included 5 and 34 patients with complete and partial responses, respectively. The median duration of progression-free survival was 13.6 months, and the median duration of response was 14.9 months. The median duration of overall survival was not reached. No treatment-related deaths were reported in this patient population. Of the 30 cases analyzed via immunohistochemistry, 13 (43.3%) were found to be PD-L1–negative; according to the investigators, PD-L1 expression was associated with favorable responses. Somatic mutations of PKD1 and KAT6A were found to be associated with responses to therapy, the study authors reported.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.